Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities.

[1]  Holger Stark,et al.  Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.

[2]  M. Nishibori,et al.  Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. , 2001, Structure.

[3]  J. Schwartz,et al.  Different antagonist binding properties of human and rat histamine H3 receptors. , 2001, Bioorganic & medicinal chemistry letters.

[4]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[5]  P. Chazot,et al.  Immunological identification of the mammalian H3 histamine receptor in the mouse brain , 2001, Neuroreport.

[6]  K. Tanaka,et al.  Molecular cloning and characterization of a new human histamine receptor, HH4R. , 2000, Biochemical and biophysical research communications.

[7]  C R Ganellin,et al.  Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.

[8]  M. Erlander,et al.  Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  J. Schwartz,et al.  Cloning and cerebral expression of the guinea pig histamine H3 receptor: evidence for two isoforms , 2000, Neuroreport.

[10]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[11]  J. Schwartz,et al.  General construction pattern of histamine H3-receptor antagonists: change of a paradigm. , 1998, Bioorganic & medicinal chemistry letters.

[12]  J. Schwartz,et al.  Development of FUB 181, a Selective Histamine H3‐Receptor Antagonist of High Oral in Vivo Potency with 4‐(?gv‐(Arylalkyloxy)alkyl)‐1H‐imidazole Structure , 1998, Archiv der Pharmazie.

[13]  H. Stark,et al.  Improvement by FUB 181, a novel histamine H3-receptor antagonist, of learning and memory in the elevated plus-maze test in mice , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  R. Leurs,et al.  Therapeutic potential of histamine H3 receptor agonists and antagonists. , 1998, Trends in pharmacological sciences.

[15]  H. Haas,et al.  International Union of Pharmacology. XIII. Classification of histamine receptors. , 1997, Pharmacological reviews.

[16]  R. Leurs,et al.  Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats , 1996, British journal of pharmacology.

[17]  K. Matsuno,et al.  Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. , 1996, European journal of pharmacology.

[18]  J. Schwartz,et al.  Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. , 1996, European journal of pharmacology.

[19]  J. Schwartz,et al.  Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity. , 1996, Journal of medicinal chemistry.

[20]  K. Onodera,et al.  Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus-maze test in mice. , 1995, Life sciences.

[21]  J. Schwartz,et al.  [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[22]  J. Schwartz,et al.  S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[23]  S. Vincent,et al.  Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (tacrine) and by beta-carbolines. , 1992, Biochemical pharmacology.

[24]  T. Nagasu,et al.  Novel sulfonamides as potential, systemically active antitumor agents. , 1992, Journal of medicinal chemistry.

[25]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[26]  Y. Itoh,et al.  A Highly Sensitive Assay for Histamine Using Ion‐Pair HPLC Coupled with Postcolumn Fluorescent Derivatization: Its Application to Biological Specimens , 1992, Journal of neurochemistry.

[27]  Angelo Vedani,et al.  A new force field for modeling metalloproteins , 1990 .

[28]  J. Schwartz,et al.  Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. , 1989, European journal of pharmacology.

[29]  J. Schwartz,et al.  Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors , 1987, Neuroscience.

[30]  J. Schwartz,et al.  Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.

[31]  P. Kollman,et al.  An all atom force field for simulations of proteins and nucleic acids , 1986, Journal of computational chemistry.

[32]  J. Schwartz,et al.  Autoregulation of histamine release in brain by presynaptic H3-receptors , 1985, Neuroscience.

[33]  R. Bowsher,et al.  Rat histamine N-methyltransferase. Quantification, tissue distribution, purification, and immunologic properties. , 1983, The Journal of biological chemistry.

[34]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[35]  O. Mitsunobu.  The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products , 1981 .

[36]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[37]  J. Kelley,et al.  Attempted inhibition of histidine decarboxylase with beta-alkyl analogues of histidine. , 1977, Journal of medicinal chemistry.

[38]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[39]  J. Schwartz,et al.  Catabolism of 3 H-histamine in the rat brain after intracisternal administration. , 1971, European journal of pharmacology.

[40]  V. P. Whittaker,et al.  SOME PROPERTIES OF SYNAPTIC MEMBRANES ISOLATED FROM THE CENTRAL NERVOUS SYSTEM * , 1966, Annals of the New York Academy of Sciences.

[41]  A. Surrey,et al.  The Role of Phenol in the Reaction of 4,7-Dichloroquinoline with Novol Diamine , 1951 .

[42]  Roland L. Dunbrack,et al.  Comparative modeling of CASP3 targets using PSI‐BLAST and SCWRL , 1999, Proteins.

[43]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[44]  J. Schwartz,et al.  Histaminergic transmission in the mammalian brain. , 1991, Physiological reviews.

[45]  M. Nishibori,et al.  9-Amino-1,2,3,4-tetrahydroacridine is a potent inhibitor of histamine N-methyltransferase. , 1991, Japanese journal of pharmacology.

[46]  C. R. Ganellin,et al.  Pharmacology of Histamine Receptors , 1982 .

[47]  A. Hirshfeld,et al.  The synthesis of zapotidine. , 1967, Tetrahedron.